Pexidartinib is a tyrosine kinase inhibitor utilized as a targeted therapy for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) associated with severe morbidity or functional limitations.… Read more
Pexidartinib is a tyrosine kinase inhibitor utilized as a targeted therapy for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) associated with severe morbidity or functional limitations. This antineoplastic agent functions by selectively inhibiting the colony-stimulating factor 1 receptor (CSF1R) signaling pathway, which is instrumental in the proliferation of tumor cells. To support the rigorous analytical requirements of pharmaceutical development and quality control, this category includes high-quality Pexidartinib reference standards, including related substances, potential impurities, and stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories during method validation, impurity profiling, and quantitative analysis, enabling accurate identification and measurement of compounds throughout the drug lifecycle. By providing reliable benchmarks for consistency and precision, these reference standards ensure that analytical methods remain robust and compliant with regulatory expectations in the assessment of API quality and stability.